Antidiabetic activity in STZ-induced diabetic Wistar rat assessed as body weight at 15 mg/kg, po administered on day 7 post STZ challenge measured immediately post dosage (Rvb = 319.4 +/- 6.9 g)
Antidiabetic activity in STZ-induced diabetic Wistar rat assessed as body weight at 15 mg/kg, po administered for 15 days post STZ challenge measured on day 21 (Rvb = 319.4 +/- 6.9 g)
Antidiabetic activity in STZ-induced diabetic Wistar rat assessed as change in fasting blood glucose level at 15 mg/kg, po administered on day 7 post STZ challenge measured immediately post dosage by glucometry (Rvb = 72.90 +/- 5.2 mg/dl)
Antidiabetic activity in STZ-induced diabetic Wistar rat assessed as change in fasting blood glucose level at 15 mg/kg, po administered for 7 days post STZ challenge measured on day 14 by glucometry (Rvb = 72.90 +/- 5.2 mg/dl)
Antidiabetic activity in STZ-induced diabetic Wistar rat assessed as decrease in blood glucose level at 15 mg/kg, po administered for 15 days post STZ challenge measured on day 21 by glucometry relative to control
Antidiabetic activity in STZ-induced diabetic Wistar rat blood assessed as creatinine level at 15 mg/kg, po administered for 15 days (Rvb = 0.56 +/- 0.03 mg/dl)
Antidiabetic activity in STZ-induced diabetic Wistar rat blood assessed as urea level at 15 mg/kg, po administered for 15 days (Rvb = 62.98 +/- 6.21 mg/dl)
Antidiabetic activity in STZ-induced diabetic Wistar rat blood assessed as cholesterol level at 15 mg/kg, po administered for 15 days (Rvb = 80.09 +/- 9.35 mg/dl)
Antidiabetic activity in STZ-induced diabetic Wistar rat blood assessed as HDL level at 15 mg/kg, po administered for 15 days (Rvb = 36.31 +/- 0.51 mg/dl)
Antidiabetic activity in STZ-induced diabetic Wistar rat blood assessed as LDL level at 15 mg/kg, po administered for 15 days (Rvb = 23.11 +/- 9.82 mg/dl)
Antioxidant activity in STZ-induced diabetic Wistar rat liver assessed as catalase level measured as H2O2 consumption per mg of protein at 15 mg/kg, po administered for 15 days (Rvb = 68.9 +/- 11.1 microM/min)
Antioxidant activity in STZ-induced diabetic Wistar rat liver assessed as glutathione peroxidase level measured as NADPH consumption per mg of protein at 15 mg/kg, po administered for 15 days (Rvb = 10 +/- 0.6 microM/min)
Antioxidant activity in STZ-induced diabetic Wistar rat liver assessed as SOD level measured per mg of protein at 15 mg/kg, po administered for 15 days by NBT reduction test (Rvb = 0.22 +/- 0.06 microM/min)
Antidiabetic activity in STZ-induced diabetic Wistar rat liver assessed as effect on central vein architecture at 15 mg/kg, po administered for 15 days by hematoxylin/eosin staining based microscopy
Antidiabetic activity in STZ-induced diabetic Wistar rat assessed as effect on hepatocytes surrounding central vein architecture at 15 mg/kg, po administered for 15 days by hematoxylin/eosin staining based microscopy
Antidiabetic activity in STZ-induced diabetic Wistar rat assessed as effect on islets of langerhans morphology at 15 mg/kg, po administered for 15 days by fluorescence microscopy